0000000000041251

AUTHOR

Nefissa Hammache

showing 2 related works from this author

New Perspective in Atrial Fibrillation

2020

International audience; Despite a large number of publications on this subject, the pathophysiological mechanisms involved in atrial fibrillation (AF) onset and recurrence are uncertain [...]

medicine.medical_specialtyeducationMEDLINElcsh:Medicinemacromolecular substances030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine0502 economics and businessmedicineIntensive care medicine[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industrylcsh:R05 social sciencesPerspective (graphical)Subject (documents)Atrial fibrillationGeneral Medicinemedicine.disease3. Good healthn/aEditorial050211 marketingbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treate…

2021

Background We assessed the impact of preprocedural plasma levels of MRproANP (midregional N‐terminal pro–atrial natriuretic peptide) and sST2 (soluble suppression of tumorigenicity 2) on recurrence of atrial fibrillation (AF) at 1 year after catheter ablation of AF. Methods and Results This was a prospective, multicenter, observational study including patients undergoing catheter ablation of AF. MRproANP and sST2 were measured in a peripheral venous blood preprocedure, and MRproANP was assessed in the right and left atrial blood during ablation. The primary end point was recurrent AF between 3 and 12 months postablation, defined as a documented (>30 seconds) episode of AF, flutter, or a…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentBiorhythmCatheter ablation030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineHeart RatePredictive Value of TestsRecurrenceRisk FactorsInternal medicinecatheter ablationAtrial FibrillationmedicineNatriuretic peptideHumansIn patientArrhythmia and Electrophysiology030212 general & internal medicineHeart AtriaProspective StudiesOriginal ResearchAgedsST2business.industryMRproANPbiomarkersAtrial fibrillationPlasma levelsMiddle Agedmedicine.diseaseInterleukin-1 Receptor-Like 1 ProteinUp-RegulationHeart RhythmTreatment OutcomePro atrial natriuretic peptideCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCatheter Ablation and Implantable Cardioverter-DefibrillatorAtrial Natriuretic FactorJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct